Article

Anterior chamber IOLs have evolved over time

There are many locations within the eye that an IOL can be placed. Most often, lenses are placed in the bag, but they may be placed in the sulcus, sewn into the posterior chamber, or sewn into or clipped onto the iris. Another location can be in the anterior chamber. Let's look at the evolution of anterior chamber IOLs (AC IOLs) in this month's column.

There are many locations within the eye that an IOL can be placed. Most often, lenses are placed in the bag, but they may be placed in the sulcus, sewn into the posterior chamber, or sewn into or clipped onto the iris. Another location can be in the anterior chamber. Let's look at the evolution of anterior chamber IOLs (AC IOLs) in this month's column.

Inflammation was an early problem with the implants; anti-inflammatory medications had yet to be developed. Pupillary occlusion and secondary glaucoma were not uncommon. Later complications included secondary membranes and lens dislocations, which occurred primarily due to the weight and size of the lens. By 1960, most AC IOLs were abandoned because of a cited 13% to 15% incidence of dislocations and an 8% to 10% incidence of glaucoma.

Some modifications Choyce's lenses were termed Mark lenses. The Mark was first implanted in 1956 as a modification of Strampelli's lens, and his Mark VIII lens was first implanted in 1963; this was his most used implant. It was a ridged, quadrangular lens having a 6-mm optic, four-point fixation, and a chord length of between 11 and 14 mm. Choyce used this lens for secondary implants in either extracapsular or intracapsular extractions.

Colored lenses were also used inpatients with albinism to minimize the iris transillumination.

In 1977 and 1978, a number of cases with complications of bleeding, elevated IOP, and iritis were reported in the literature. These reports increased, and a syndrome-the uveitis, glaucoma, and hyphema (UGH) syndrome-was described.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.